{"entity":{"id":"nct07788222","kind":"trial","name":"Sacituzumab Govitecan and Q901 in Advanced TNBC","aka":[],"tldr":"A phase 2 trial of sacituzumab govitecan in triple-negative breast cancer, run by Yonsei University, not yet recruiting.","summary":"Sacituzumab Govitecan and Q901 in Advanced TNBC is a phase 2, interventional study registered as NCT07788222 by Yonsei University, with a registry enrolment figure of 48 participants, started 2026-09-01 and due to reach its primary completion in 2028-05-31. Interventions recorded: Sacituzumab govitecan and Q901. Conditions listed: Triple Negative Breast Neoplasms. Triple-negative eligibility wording from the registry: \"Patients with histologically or cytologically confirmed triple-negative breast cancer (TNBC) who have received at least 2 prior lines of systemic anticancer therapy for recurrent, metastatic, or unresectable disease\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07788222","url":"https://clinicaltrials.gov/study/NCT07788222"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early","tnbc-metastatic"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["sacituzumab-govitecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07788222","phase":"2","setting":"Multi-center, Open-label, Single-arm Phase II Clinical Trial of Sacituzumab-Govitecan Plus Q901 in Advanced TNBC","sponsor":"Yonsei University","enrolled":48,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07788222/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"},{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}